Vaxxinity, Inc. (VAXX)
OTCMKTS
· Delayed Price · Currency is USD
0.0140
0.00 (0.00%)
May 1, 2025, 4:00 PM EDT
Vaxxinity Employees
As of December 31, 2023, Vaxxinity had 65 total employees, including 57 full-time and 8 part-time employees. The number of employees decreased by 24 or -26.97% compared to the previous year.
Employees
65
Change (1Y)
-24
Growth (1Y)
-26.97%
Revenue / Employee
n/a
Profits / Employee
-$933,344
Market Cap
1.77M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 65 | -24 | -26.97% |
| Dec 31, 2022 | 89 | 0 | - |
| Dec 31, 2021 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 64 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Vaxxinity News
- 11 months ago - Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine - GlobeNewsWire
- 1 year ago - Vaxxinity Issues Shareholder Letter - GlobeNewsWire
- 1 year ago - Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - GlobeNewsWire
- 1 year ago - Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewsWire
- 1 year ago - Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 1 year ago - Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024 - GlobeNewsWire
- 1 year ago - Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - GlobeNewsWire
- 1 year ago - Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - GlobeNewsWire